Updates on JAK Inhibitor Safety, COVID-19 Vaccination in Immunosuppressed Patients & More

ACR CONVERGENCE 2021—The ACR Convergence 2021 meeting reflected the continued advancement of science and practical research in the field of rheumatoid arthritis (RA). Among the most important topics this year in RA was the evolution of the risk-benefit profile of Janus kinase (JAK) inhibitors, for which new safety data emerged in a series of related... [Read More]

Source: The Rheumatologist - December 7, 2021 Category: Rheumatology Authors: Jeffrey Curtis, MD, MS, MPH Tags: ACR Convergence Conditions Meeting Reports Research Reviews Rheumatoid Arthritis ACR Convergence 2021 ACR Convergence 2021 – RA Source Type: research